– USA, MA – scPharmaceuticals Inc. (NASDAQ: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Dr. William Abraham, M.D., to its Board of Directors.
Dr. Abraham currently serves as Professor of Internal Medicine, Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients.
“I could not be more excited to welcome Dr. Abraham to our Board. His rare blend of academic and industry expertise in the field of heart failure will add a unique perspective that will serve us well,” said CEO, John Tucker. “We continue to work tirelessly to obtain approval for FUROSCIX as a potential new treatment option for the millions of worsening heart failure patients who suffer from congestion due to fluid overload, and look forward to working with Dr. Abraham and the other Board members toward that goal.”
About Dr. William Abraham
William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE, also serves as Deputy Director of the Dorothy M. Davis Heart and Lung Research Institute. Dr. Abraham previously held faculty appointments at the University of Colorado, the University of Cincinnati and the University of Kentucky. Dr. Abraham’s research interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, sleep-disordered breathing in heart failure and clinical drug and device trials in heart failure and cardiac transplantation. He has received grants from the National Institutes of Health, the American College of Cardiology and the Aetna Quality Care Foundation and has served as principal investigator in more than 100 clinical drug and device trials.
In addition to authoring more than 1,000 original papers, abstracts, book chapters and review articles, Dr. Abraham has co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment. He serves on the editorial boards of several major journals and as a scientific reviewer for such publications as Circulation, the European Heart Journal, and the Journal of the American College of Cardiology.
Dr. Abraham has been recognized as one of the ‘Best Doctors in America’ for 18 consecutive years. He was named as one of The World’s Most Influential Scientific Minds and named to the Highly Cited Researchers list by Clarivate Analytics. In 2017, he received the Distinguished Scientist Award from the American College of Cardiology.
“There is an enormous unmet need for new outpatient interventions to alleviate signs and symptoms associated with congestion in heart failure,” said Dr. Abraham. “If approved, I believe FUROSCIX has the potential to change the worsening heart failure treatment paradigm while realizing cost savings for public and private payers alike.”
Dr. Abraham received his M.D. from Harvard Medical School before completing a residency in internal medicine and fellowships in cardiology and heart failure/cardiac transplantation at the University of Colorado Health Sciences Center. He is board-certified in internal medicine and advanced heart failure and transplant cardiology.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA.
For more information : https://www.scpharmaceuticals.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
